Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.60 |
| ▸ | BRD2 | P25440 | 8/20 | 0.56 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.56 |
| ▸ | CCL2 | P13500 | 3/20 | 0.56 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1907797 | 0.84 | BRD4 (0.55) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL1898913 | 0.83 | BRD4 (0.71) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL13727152 | 0.82 | BRD4 (0.89) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL13824094 | 0.82 | BRD4 (0.69) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL1905563 | 0.82 | BRD4 (0.59) | BRD4BRD2BRD3CCL2 | |
| SCHEMBL19459567 | 0.79 | BRD4 (0.74) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL11907753 | 0.77 | BRD4 (0.54) | BRD4BRD2BRD3CCL2EP300 | |
| SCHEMBL11978807 | 0.76 | BRD2 (0.49) | BRD4BRD2BRD3 | |
| SCHEMBL11980255 | 0.76 | BRD2 (0.65) | BRD4BRD2BRD3 | |
| SCHEMBL222857 | 0.74 | BRD4 (0.85) | BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496558-B1 | TETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2496558-B1 | TETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8580957-B2 | Thetrahydroquinolines derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580957-B2 | Thetrahydroquinolines derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580957-B2 | Thetrahydroquinolines derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2496558-A1 | THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011054848-A1 | THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | BRD4, BRDT, BRPF3 | BRD4 1/4885BRD2 5/4885BRD3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.